Business Context and Reporting Period
Company: Neogen Corporation (NEOG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended May 31, 2026
Business Overview: Neogen develops, manufactures, and markets products and services for food and animal safety. Operations are organized into two segments: Food Safety (diagnostic test kits, culture media) and Animal Safety (veterinary instruments, pharmaceuticals, genomics services). The company operates globally with significant international revenue (51.2% in FY2026).
Key Financial Metrics
| Metric (in millions) | FY 2026 | FY 2025 |
|---|---|---|
| Total Revenues | $870.4 | $894.7 |
| Gross Profit | $408.5 | $421.4 |
| Gross Margin | 46.9% | 47.1% |
| Operating Loss | $(21.6) | $(1,061.0) |
| Net Loss | $(7.9) | $(1,092.0) |
| Operating Cash Flow | $83.2 | $58.2 |
| Cash and Equivalents (End of Period) | $185.5 | $129.0 |
| Total Debt | $800.0 | $902.4 |
Note: FY2025 results included a non-cash goodwill impairment charge of $1,059.3 million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% ($24.3 million) primarily due to the divestiture of the Cleaners and Disinfectants business ($55.6 million impact), partially offset by organic growth ($17.3 million) and favorable foreign exchange ($14.0 million).
- Profitability Improvement: Operating loss narrowed significantly from $(1,061.0) million to $(21.6) million. This improvement is largely attributable to the absence of the $1,059.3 million goodwill impairment recorded in FY2025.
- Segment Performance:
- Food Safety: Revenue increased slightly ($3.0 million) driven by growth in indicators and pathogen detection, offset by the divestiture.
- Animal Safety: Revenue decreased 11% ($27.3 million) due to the divestiture and lower sales of veterinary instruments and rodent control products.
- Divestitures: Completed the sale of the Cleaners and Disinfectants business in Q1 FY2026, recognizing a gain of $76.4 million. Entered a definitive agreement to sell the Genomics business to Zoetis for $160.0 million (pending regulatory approval).
- Debt Reduction: Total debt decreased by approximately $102 million due to prepayments and refinancing activities.
Guidance, Outlook, and Risks
- Outlook: Management expects steady growth in the Food Safety market in FY2027. The Animal Safety market remains near cyclical lows, though the company is optimistic about future growth via distribution partnerships.
- Strategic Initiatives: Focus on commercial excellence, innovation, and operational efficiency. Key priority is the transition of Petrifilm manufacturing from 3M to Neogen's Lansing facility, expected to be substantially complete in FY2027.
- Restructuring: Initiated a plan in Q2 FY2026 to reduce global headcount by approximately 10% to right-size the cost base.
- Key Risks:
- Transaction Risks: Uncertainty regarding the closing of the Genomics divestiture and the successful integration of the 3M Food Safety business (specifically Petrifilm manufacturing transition).
- Trade & Tariffs: Increased tariffs and trade policy changes are raising material input costs and impacting international sales.
- Legal & Product Liability: Ongoing shareholder litigation regarding the 3M transaction and a voluntary recall of Vet HyCoat product (microbial contamination) with associated claims.
- Internal Controls: Previously identified material weaknesses in internal controls were remediated as of May 31, 2026.
Investor Verification Checklist
- Genomics Divestiture Status: Verify the timeline and regulatory approval status of the $160 million sale to Zoetis, specifically regarding the second-phase reviews by Australian and New Zealand regulators.
- Petrifilm Transition: Monitor progress on moving Petrifilm manufacturing from 3M to Neogen facilities to ensure cost synergies are realized and duplicative costs are eliminated.
- Debt Covenants: Confirm continued compliance with financial covenants (leverage and interest coverage ratios) given the high debt load ($800 million).
- Product Recall Impact: Assess the financial impact of the Vet HyCoat recall and potential liability from related lawsuits.
- Goodwill Valuation: Review the assumptions used in the FY2026 goodwill impairment test to ensure no further impairments are likely given the company's market position.